

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6812153

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EXUMA BIOTECHNOLOGY SEZC	06/28/2021
RECEIVING PARTY DATA	
Name:	EXUMA BIOTECH CORP.
Street Address:	625 N. FLAGLER DR., SUITE 625
City:	WEST PALM BEACH
State/Country:	FLORIDA
Postal Code:	33401
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17110028
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	561-650-5048
Email:	gschreiber@exumabio.com
Correspondent Name:	GREG SCHREIBER
Address Line 1:	625 N. FLAGLER DR., SUITE 625
Address Line 4:	WEST PALM BEACH, FLORIDA 33401
ATTORNEY DOCKET NUMBER:	F1.001.US.05
NAME OF SUBMITTER:	MICHAEL MAND
SIGNATURE:	/Michael Mand/
DATE SIGNED:	07/14/2021
Total Attachments: 3	
source=F1.001.US.05 Assignment EXUMA SEZC to EXUMA CORP#page1.tif	
source=F1.001.US.05 Assignment EXUMA SEZC to EXUMA CORP#page2.tif	
source=F1.001.US.05 Assignment EXUMA SEZC to EXUMA CORP#page3.tif	

ASSIGNMENT

In consideration of good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, effective as of the signature date of the Assignor below, the undersigned **EXUMA Biotechnology SEZC**, a corporation of The Cayman Islands, having a place of business at 90 N Church Street Georgetown, Grand Cayman, Cayman Islands KY1-1003 ("Assignor") does hereby assign, sell and transfer to:

EXUMA BIOTECH CORP., a corporation of the State of Delaware having a place of business at 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401, USA ("Assignee"),

its successors and assigns, the entire right, title and interest in the invention and/or improvements of the undersigned disclosed in the patent applications and other rights shown below:

- (a) United States Patent Application, Serial No. 17/110,028 filed on December 2, 2020, entitled **METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF MPL**; and,
- (b) any and all inventions, improvements, know-how, and other subject matter described, disclosed, or contained (whether claimed or not) in any of the foregoing applications and patents, whether developed solely or jointly with others; and,
- (c) the right to file foreign applications under the provisions of any convention or treaty and claim priority based on any of the foregoing applications in the United States or any other country; and,
- (d) all international, divisional, continuing, design, utility model, substitute, renewal, reissue, reexamination, and all other applications for patent which have been or shall be filed in the United States and all foreign countries that claim priority to or through, any of the foregoing applications; and,
- (e) all original, reissued and reexamined patents which have been or shall be issued in the United States or any other country on or resulting from any of the applications referenced in one or more of (a) through (d) above; and,
- (f) the copyright in any and all material described, disclosed, or contained in the foregoing applications and patents; and,
- (g) any and all other rights described in or provided by any of the above.

The undersigned Assignor warrant itself to be the owner of a right, title and interest in said invention or improvements and other rights in the same and to have the right to make this assignment, and further

warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The undersigned hereby authorize and request all patent offices to issue any Patent and/or other rights resulting from any of the applications and/or rights references in one or more of (a) through (g) above to said Assignee.

For said considerations the undersigned hereby agree, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all papers and documents and perform any and all acts reasonably necessary in connection with the filing, prosecution, and issuance of each of the patent applications listed herein, including, but not limited to, any necessary oath, affidavit or declaration relating thereto, and any application for the reissue or extension of any Patent that may be granted upon said applications and any and all applications and other documents for Patent and/or other rights on said invention or improvements, or other rights, that said Assignee, its successors or assigns may deem necessary or expedient, and for the said considerations the undersigned authorize said Assignee to apply for patents and/or other rights for said invention improvements in its own name in such countries where such procedure is proper and further agree, upon the request of said Assignee, its successors and assigns, to cooperate to the best of the ability of the undersigned with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents and/or other rights, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain, maintain and enforce said Patents and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Patents and/or other rights will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Patents and/or other rights will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.

Signature by Assignor:

Signature: _____ Date: 6/28/2021

Signature of legal representative of EXUMA Biotechnology SEZC

James Samuels, President

EXUMA Biotechnology SEZC

Witness Signature: Reborah Johann Date: 6/28/2021

Witness Name: Reborah Johann

Signature by Assignee:

Signature: _____

Date: _____

6/28/2021

Signature of legal representative of EXUMA BIOTECH CORP.

Gregory Ian Frost, CEO

EXUMA BIOTECH CORP.

Witness Signature: _____

Date: _____

6/28/2021

Witness Name: _____

Deborah Schann